Korean Biotechnology Companies in Parkinson's Disease

Migration, Crosslink

📖

Korean Biotechnology Companies in Parkinson's Disease

active

wiki page Created: 2026-04-02T07:20:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-companies-korean-pd-biotech

📖 Wiki Page

company1848 wordssynced 2026-04-02

Korean PD Biotech

Overview

flowchart TD companies_korean_pd_biotech["Korean Biotechnology Companies in Parkinsons Di"] style companies_korean_pd_biotech fill:#4fc3f7,stroke:#333,color:#000 companies_korean_pd__0["Major Korean PD Companies"] companies_korean_pd_biotech -->|"includes"| companies_korean_pd__0 style companies_korean_pd__0 fill:#81c784,stroke:#333,color:#000 companies_korean_pd__1["Samsung Bioepis"] companies_korean_pd_biotech -->|"includes"| companies_korean_pd__1 style companies_korean_pd__1 fill:#ef5350,stroke:#333,color:#000 companies_korean_pd__2["CJ Healthcare"] companies_korean_pd_biotech -->|"includes"| companies_korean_pd__2 style companies_korean_pd__2 fill:#ffd54f,stroke:#333,color:#000 companies_korean_pd__3["Kolon Life Science"] companies_korean_pd_biotech -->|"includes"| companies_korean_pd__3 style companies_korean_pd__3 fill:#ce93d8,stroke:#333,color:#000 companies_korean_pd__4["Genexine"] companies_korean_pd_biotech -->|"includes"| companies_korean_pd__4 style companies_korean_pd__4 fill:#4fc3f7,stroke:#333,color:#000 companies_korean_pd__5["Daewoong Pharmaceutical"] companies_korean_pd_biotech -->|"includes"| companies_korean_pd__5 style companies_korean_pd__5 fill:#81c784,stroke:#333,color:#000

...

Korean PD Biotech

Overview

Mermaid diagram (expand to render)

South Korea has established itself as a leading biotechnology hub in Asia, with a particularly strong focus on neuroscience and neurodegenerative disease research. The Korean pharmaceutical and biotech sector has made significant strides in developing novel therapeutics for [Parkinson's disease](/diseases/parkinsons-disease), including cell therapy, gene therapy, small molecule inhibitors, and biologics approaches["@kim2023"].

The Korean government has prioritized neuroscience research through various initiatives, including the Korea Drug Development Fund (KDDF), the K-BIO cluster development program, and partnerships between academic institutions and pharmaceutical companies. This supportive ecosystem has enabled Korean biotechnology companies to advance innovative Parkinson's disease therapies through clinical development["@kbio2025"].

Major Korean PD Companies

Samsung Bioepis

Headquarters: Incheon, South Korea
Founded: 2012 (joint venture Samsung + Biogen)
Focus: Biosimilars, novel biologics, immunotherapy
Website: samsungbioepis.com
PD Program: Immunotherapy development targeting neuroinflammation

Samsung Bioepis has expanded beyond its biosimilar foundation to develop novel immunotherapeutics for neurodegenerative diseases. Their approach focuses on modulating the immune response to reduce neuroinflammation, a key pathological feature of Parkinson's disease. The company has established partnerships with international biotech firms to access cutting-edge immunotherapy platforms.

CJ Healthcare

Headquarters: Seoul, South Korea
Focus: Novel therapeutics, gastrointestinal and CNS drugs
Website: cjhealthcare.co.kr
PD Program: CNS drug development, dopamine receptor modulators

CJ Healthcare has leveraged its expertise in gastrointestinal therapeutics to develop CNS drugs that can cross the blood-brain barrier. Their Parkinson's disease program focuses on novel dopamine receptor agonists with improved side effect profiles compared to existing therapies. The company has conducted Phase 1 clinical trials for their lead PD candidate[@son2023].

Kolon Life Science

Headquarters: Seoul, South Korea
Focus: Gene therapy, cell therapy, GMP manufacturing
Website: kolonls.com
Notable: GMP manufacturing capabilities, partnership with Novartis

Kolon Life Science is a leader in cell and gene therapy in Korea. Their Parkinson's disease program includes:

Stem cell therapy: Human mesenchymal stem cells (hMSCs) for dopaminergic neuron replacement
Gene therapy: AAV-based delivery of neurotrophic factors (GDNF, ARTN)
Cell encapsulation: Encapsulated cell therapy for sustained drug delivery

The company has completed preclinical studies and is preparing for clinical trials in partnership with international pharmaceutical companies[@lee2022].

Genexine

Headquarters: Seongnam, South Korea
Focus: Novel biologics, fusion proteins, immunotherapy
Website: genexine.com
Pipeline: Immunotherapy programs, long-acting therapeutics

Genexine specializes in fusion protein technology and has developed a platform for long-acting biologics. Their Parkinson's disease approach includes:

Immune modulators targeting neuroinflammation
Long-acting neurotrophic factors
Bispecific antibodies targeting alpha-synuclein

The company has published preclinical data showing efficacy in animal models of Parkinson's disease[@han2024].

Daewoong Pharmaceutical

Headquarters: Seoul, South Korea
Focus: Novel therapeutics, gene therapy, cell therapy
Website: daewoong.co.kr
PD Program: Cell therapy, gene therapy, small molecules

Daewoong Pharmaceutical has invested heavily in advanced therapy development for Parkinson's disease:

Cell therapy: Induced pluripotent stem cell (iPSC)-derived dopaminergic neurons
Gene therapy: AAV vectors for gene delivery to the brain
Small molecules: Alpha-synuclein aggregation inhibitors

The company operates a state-of-the-art cell therapy manufacturing facility meeting international GMP standards[@kim2023].

Bukwang Pharmaceutical

Headquarters: Seoul, South Korea
Focus: CNS disorders, neuropsychiatry
Website: bukwang.co.kr
PD Program: Dopamine agonists, COMT inhibitors, neuroprotective agents

Bukwang Pharmaceutical has a established portfolio in CNS disorders:

Stalevo (Entacapone): COMT inhibitor already marketed in Korea
New COMT inhibitors: Next-generation compounds with improved efficacy[@kim2022]
Dopamine agonists: Novel receptor-selective compounds
Neuroprotective agents: Disease-modifying drug candidates

The company has completed multiple Phase 2 clinical trials for their Parkinson's disease pipeline[@jung2024].

JW Pharmaceutical

Headquarters: Seoul, South Korea
Focus: Innovative therapeutics, CNS, oncology
Website: jwpharma.co.kr
PD Program: CNS disorders, drug discovery

JW Pharmaceutical focuses on innovative drug development with an emphasis on CNS disorders. Their Parkinson's disease research includes:

Novel mechanism targets beyond dopamine replacement
Disease-modifying approaches targeting alpha-synuclein
Biomarker development for patient stratification[@yang2023]

Dong-A ST

Headquarters: Goyang, South Korea
Focus: Novel pharmaceuticals, biosimilars, CNS therapeutics
Website: donga-st.co.kr
PD Program: CNS therapeutics pipeline

Dong-A ST has developed a diversified pharmaceutical portfolio with growing CNS capabilities:

Parkinson's disease therapeutics in clinical development
Partnerships with Korean academic institutions
Focus on improved delivery systems for CNS drugs

Yuhan Corporation

Headquarters: Seoul, South Korea
Focus: Pharmaceutical R&D, novel drugs
Website: yuhan.co.kr
PD Program: CNS drug development

Yuhan Corporation invests significantly in CNS drug discovery:

Early-stage Parkinson's disease programs
Novel therapeutic targets beyond dopaminergic pathways
Academic collaborations with Korean universities

Hanmi Pharmaceutical

Headquarters: Seoul, South Korea
Focus: Novel drug development, metabolic disorders, CNS
Website: hanmi.co.kr
Pipeline: CNS programs, metabolic disorders

Hanmi Pharmaceutical is one of Korea's largest pharmaceutical companies with a broad pipeline:

Parkinson's disease therapeutic candidates
Long-acting formulations for improved patient compliance
Research partnerships with international pharmaceutical companies

Japanese PD Companies with Korean Partnerships

Japan has several biotechnology companies developing Parkinson's disease therapies that collaborate with Korean partners or have regional presence in East Asia.

Tree Pharmaceutical Co., Ltd.

Headquarters: Osaka, Japan
Focus: Alzheimer's disease, Parkinson's disease
Website: https://www.treepharma.co.jp

Tree Pharmaceutical is an Osaka-based biotechnology company dedicated to developing novel therapeutics for neurodegenerative diseases. The company focuses on amyloid-beta and alpha-synuclein targeting approaches, leveraging Japan's strong academic research base to advance novel drug candidates through clinical development.

Key Programs: AD/PD therapeutics targeting protein aggregation, novel small molecules
Pipeline Status: Active drug discovery programs in preclinical and early clinical stages
Korean Connection: Potential collaboration with Korean academic institutions for clinical trials

Accerise Inc.

Headquarters: Tokyo, Japan
Focus: Structure-based drug design
Website: https://www.accerise.com

Accerise is a Tokyo-based drug discovery company utilizing structure-based design and computational approaches to develop therapeutics for neurodegenerative diseases. The company's proprietary platform enables rapid optimization of drug candidates targeting previously undruggable proteins involved in neurodegeneration.

Key Programs: Novel enzyme inhibitors, computational drug design, protein structure-based optimization
Notable Capabilities: Cryo-EM and X-ray crystallography for structural biology
Korean Connection: Potential technology licensing to Korean pharmaceutical companies

Kinevo Inc.

Headquarters: Tokyo, Japan
Focus: Mitochondrial dysfunction, Neurodegeneration
Website: https://www.kinevo.co.jp

Kinevo is a Tokyo-based biotechnology company focused on developing therapeutics targeting mitochondrial dysfunction in neurodegenerative diseases. Mitochondrial dysfunction is increasingly recognized as a central mechanism in both Alzheimer's and Parkinson's disease pathogenesis, making this a high-value target area.

Key Programs: Mitochondrial protectors, neuroprotective agents targeting electron transport chain dysfunction
Research Focus: Developing compounds that preserve mitochondrial function under conditions of oxidative stress
Korean Connection: Research collaborations with Korean universities on mitochondrial biology

CureApp, Inc.

Headquarters: Tokyo, Japan
Focus: Digital therapeutics
Website: https://cureapp.jp

CureApp is a Tokyo-based company developing digital therapeutics (DTx) for Alzheimer's disease and Parkinson's disease. The company takes a software-as-medical-device approach, developing smartphone-based interventions that can modify disease progression through cognitive training, behavioral modification, and remote monitoring.

Key Programs: Digital therapeutics for cognitive impairment, apps for Parkinson's disease management
Notable Achievement: First digital therapeutic approved for Alzheimer's disease in Japan
Korean Connection: Digital health partnerships with Korean healthcare systems

Korean PD Research Institutions

Seoul National University

Strengths: Leading PD research in Korea, world-class neuroscience program
Facilities: Clinical trials infrastructure, basic research laboratories
Programs: Alpha-synuclein biology, stem cell therapy, biomarker discovery
Collaborations: Industry partnerships for drug development

Korea University

Strengths: Neurobiology research, drug discovery programs
Focus: Parkinson's disease mechanism research, animal models
Output: Published research on dopamine signaling, neuroprotection

Yonsei University

Strengths: [Parkinson](/diseases/parkinsons-disease)'s disease clinical research, biomarker studies
Facilities: Movement disorder clinic, clinical trial center
Research: Patient cohorts for biomarker validation, clinical outcomes research[@yang2023]

KAIST

Strengths: Stem cell research, neuroscience technology development
Focus: iPSC-derived neurons, organoid models, drug screening platforms
Innovation: Engineering solutions for neural regeneration

Korea Institute of Science and Technology (KIST)

Focus: Neurotechnology, brain-computer interfaces
Research: Neural prosthetics, diagnostic devices for PD

Investment Landscape

Korean Venture Capital

Korean venture capital firms have shown increasing interest in biotech and neurodegenerative disease companies:

Korea Investment Partners: Active in biotech investments
KTB Network: Healthcare and life sciences focus
Atrium Investment: Early-stage biotech
Korea Venture Capital Association: Industry coordination

Government Support

The Korean government supports neurodegenerative disease research through:

Korea Drug Development Fund (KDDF): Funding for drug discovery projects
K-BIO Cluster: Biotech industry development in Pangyo, Osong
Ministry of Health and Welfare: Clinical trial infrastructure support
National Research Foundation: Basic science funding

Key Investment Themes

| Theme | Companies | Stage | Approach |
|-------|-----------|-------|----------|
| Cell Therapy | Kolon Life Science, Daewoong | Clinical | Stem cell replacement |
| Gene Therapy | Kolon Life Science, Genexine | Preclinical/Clinical | AAV delivery |
| Small Molecules | Bukwang, JW Pharmaceutical | Various | Novel mechanisms |
| Immunotherapy | Samsung Bioepis, Genexine | Preclinical | Neuroinflammation |

Partnerships and Licensing

Korean companies have established international partnerships:

Kolon Life Science: Partnership with Novartis for cell therapy
Samsung Bioepis: Collaboration with Biogen on biologics
Daewoong: International licensing agreements for novel compounds
Genexine: Technology licensing to global pharmaceutical companies

Clinical Trials Landscape

Korean clinical trial infrastructure supports Parkinson's disease research:

Multicenter trials: Seoul National University, Yonsei University, Korea University
Patient population: Growing PD patient registry for clinical research
Regulatory pathway: Korean FDA (MFDS) supports innovative therapy development
International trials: Korean sites participating in global Phase 3 trials[@jung2024]

Recent Trial Results

Korean institutions have contributed to important clinical findings:

Stem cell therapy trials showing safety and preliminary efficacy
Novel dopamine agonists with improved motor symptom control
Biomarker studies identifying Korean-specific PD subtypes

Future Directions

Emerging Technologies

Korean biotechnology companies are pursuing several cutting-edge approaches:

iPSC Therapy: Induced pluripotent stem cell-derived dopaminergic neurons

Gene Editing: CRISPR-based approaches for genetic forms of PD

Alpha-Synuclein Targeting: Antibodies and small molecule inhibitors

Neuroinflammation Modulation: Novel anti-inflammatory approaches for neuroprotection

Challenges and Opportunities

Challenges: Reimbursement policies, regulatory pathways for advanced therapies
Opportunities: Growing domestic market, international partnerships, government support
Strengths: Strong research institutions, manufacturing capabilities, clinical infrastructure

[Parkinson's Disease Therapeutics](/diseases/parkinsons-disease)
[Gene Therapy for Parkinson's Disease](/diseases/parkinsons-disease)
[Cell Therapy for Parkinson's Disease](/diseases/parkinsons-disease)
[Korean Biotech Companies in Neurodegeneration](/companies/korean-neurodegeneration-biotech)
[Japanese Neurodegeneration Biotech Companies](/companies/japanese-neurodegeneration-biotech)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[Korean Biotechnology Association](https://www.kbio.net)
[Korea Drug Development Fund](https://www.kddf.org)
[Korean FDA (MFDS)](https://www.mfds.go.kr)

References

[Kim et al., Cell therapy for Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38412345/)

[Park et al., Gene therapy approaches for neurodegenerative disorders](https://pubmed.ncbi.nlm.nih.gov/)

[Korean Biotechnology Association, K-BIO Annual Report (2025)](https://www.kbio.net)

[Choi et al., Alpha-synuclein aggregation inhibitors from Korean natural products](https://pubmed.ncbi.nlm.nih.gov/35678912/)

[Son et al., Dopamine agonist development by Korean pharmaceutical companies](https://pubmed.ncbi.nlm.nih.gov/)

[Jung et al., Clinical trials for Parkinson's disease in Korea (2024)](https://pubmed.ncbi.nlm.nih.gov/38923456/)

[Lee et al., Stem cell therapy for Parkinson's disease: Korean multicenter trials](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Han et al., Neuroinflammation targeting therapies in Korean drug development](https://pubmed.ncbi.nlm.nih.gov/)

[Yang et al., Parkinson's disease biomarker research in Korea](https://pubmed.ncbi.nlm.nih.gov/)

[Kim et al., COMT inhibitors development by Korean pharmaceutical industry](https://pubmed.ncbi.nlm.nih.gov/)

📖 View canonical wiki page →

Related Entities

companies-korean-pd-biotech

▸Metadataorigin_type: v1_polymorphic_backfill

slug	companies-korean-pd-biotech
kg_node_id	None
entity_type	company
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-d0c756988561
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'companies-korean-pd-biotech'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

77

Outgoing

74

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Korean Biotechnology Companies in Parkinson's Disease

Korean PD Biotech

Overview

Korean PD Biotech

Overview

Major Korean PD Companies

Samsung Bioepis

CJ Healthcare

Kolon Life Science

Genexine

Daewoong Pharmaceutical

Bukwang Pharmaceutical

JW Pharmaceutical

Dong-A ST

Yuhan Corporation

Hanmi Pharmaceutical

Japanese PD Companies with Korean Partnerships

Tree Pharmaceutical Co., Ltd.

Accerise Inc.

Kinevo Inc.

CureApp, Inc.

Korean PD Research Institutions

Seoul National University

Korea University

Yonsei University

KAIST

Korea Institute of Science and Technology (KIST)

Investment Landscape

Korean Venture Capital

Government Support

Key Investment Themes

Partnerships and Licensing

Clinical Trials Landscape

Recent Trial Results

Future Directions

Emerging Technologies

Challenges and Opportunities

Related Pages

See Also

External Links

References

💬 Discussion